Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
" In view of : - the efficacy and safety data versus placebo, - the absence of direct comparative data versus other anti-ANF agents, particularly infliximab, the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies." |
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
fpBqBKXy6gLaVRmn
